<DOC>
	<DOCNO>NCT02236403</DOCNO>
	<brief_summary>Blepharitis endemic inflammatory disease cause mainly Demodex folliculorum Demodex Brevis , This mite often associate anaerobic bacteria produce skin inflammation , intervention reduces number mite bacteria would desirable . Ivermectin macrolid compound demonstrate activity scabies lice human animal single application show good response louse eradication . In study , investigator determinate security effectiveness compound eradication mite</brief_summary>
	<brief_title>Treatment Demodex Blepharitis With Ivermectin Gel 0.1 % Plus Metronidazole 1 %</brief_title>
	<detailed_description />
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>• Patients symptomatic Demodex blepharitis duration least 3 month . Age range : 18 yeras old . Both gender ethnic group comparable local community . Able understand willing sign write informed consent Able willing cooperate investigational plan . Able willing complete mandatory followup visit . • Patients currently engage another clinical trial , unwilling unable give consent , accept randomization , return schedule visit . Children 18 . Pregnant woman expect pregnant study . Systemic immune deficient condition AIDS systemic immunosuppressant . Concomitant use ophthalmic topical medication ( exclude nonpreserved tear substitute ) . Concomitant use systemic antibiotic steroid . Contact lens wear Active ocular infection allergy Unable close eye uncontrolled blink Previous allergic reaction metronidazole / ivermectin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Blepharitis , Demodex , Ivermectin , Metronidazole</keyword>
</DOC>